JP2012525829A - 補体タンパク質Ｃ３ｂを標的とする抗体の組成物および方法 - Google Patents

補体タンパク質Ｃ３ｂを標的とする抗体の組成物および方法 Download PDF

Info

Publication number
JP2012525829A
JP2012525829A JP2012509035A JP2012509035A JP2012525829A JP 2012525829 A JP2012525829 A JP 2012525829A JP 2012509035 A JP2012509035 A JP 2012509035A JP 2012509035 A JP2012509035 A JP 2012509035A JP 2012525829 A JP2012525829 A JP 2012525829A
Authority
JP
Japan
Prior art keywords
antibody
binding
antigen
human
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012509035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525829A5 (cg-RX-API-DMAC7.html
Inventor
ビジャン・エテマド−ギルバートソン
ブレイドン・チャールズ・ギルド
キム・ヨンイン
インゴ・クラゲ
アレクサンドラ・クラウス
マイケル・ログスカ
イゴル・スプラフスキー
チャオ・ケハオ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2012525829A publication Critical patent/JP2012525829A/ja
Publication of JP2012525829A5 publication Critical patent/JP2012525829A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2012509035A 2009-05-06 2010-05-05 補体タンパク質Ｃ３ｂを標的とする抗体の組成物および方法 Pending JP2012525829A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17586009P 2009-05-06 2009-05-06
US61/175,860 2009-05-06
PCT/EP2010/056129 WO2010136311A2 (en) 2009-05-06 2010-05-05 Compositions and methods for antibodies targeting complement protein c3b

Publications (2)

Publication Number Publication Date
JP2012525829A true JP2012525829A (ja) 2012-10-25
JP2012525829A5 JP2012525829A5 (cg-RX-API-DMAC7.html) 2013-06-20

Family

ID=43063291

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012509035A Pending JP2012525829A (ja) 2009-05-06 2010-05-05 補体タンパク質Ｃ３ｂを標的とする抗体の組成物および方法

Country Status (22)

Country Link
US (1) US20100291106A1 (cg-RX-API-DMAC7.html)
EP (1) EP2427491A2 (cg-RX-API-DMAC7.html)
JP (1) JP2012525829A (cg-RX-API-DMAC7.html)
KR (1) KR20120088551A (cg-RX-API-DMAC7.html)
CN (1) CN102459334A (cg-RX-API-DMAC7.html)
AR (1) AR076655A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010252156A1 (cg-RX-API-DMAC7.html)
CA (1) CA2760757A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011002756A1 (cg-RX-API-DMAC7.html)
CO (1) CO6440515A2 (cg-RX-API-DMAC7.html)
EA (1) EA201101593A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011445A (cg-RX-API-DMAC7.html)
IL (1) IL216061A0 (cg-RX-API-DMAC7.html)
MA (1) MA33402B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011011754A (cg-RX-API-DMAC7.html)
PE (1) PE20120899A1 (cg-RX-API-DMAC7.html)
SG (1) SG175432A1 (cg-RX-API-DMAC7.html)
TN (1) TN2011000528A1 (cg-RX-API-DMAC7.html)
TW (1) TW201043638A (cg-RX-API-DMAC7.html)
UY (1) UY32612A (cg-RX-API-DMAC7.html)
WO (1) WO2010136311A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201107551B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502023A (ja) * 2013-12-24 2017-01-19 ノーベルメッド セラピューティクス インコーポレイテッド． 眼疾患を治療する組成物および方法
JP2021520195A (ja) * 2018-04-03 2021-08-19 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Ｃ３結合薬及びその使用方法

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107708A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
BRPI0712987A2 (pt) 2006-06-21 2012-04-10 Musc Found For Res Dev tratamento de doenças direcionado ao fator h do complemento
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
NZ600393A (en) 2009-11-05 2014-08-29 Alexion Cambridge Corp Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
BR112012029067A2 (pt) 2010-05-14 2019-09-24 Univ Colorado Regents grupos-alvo de receptor do complemento 2 (cr2) melhorados.
CA2803588A1 (en) 2010-06-22 2011-12-29 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the c3d fragment of complement component 3
EP2646821A4 (en) * 2010-11-29 2015-09-23 Novelmed Therapeutics Inc NEOANTIC BODY FOR THE DIAGNOSIS OF TISSUE INJURY
WO2013152024A1 (en) * 2012-04-03 2013-10-10 Novelmed Therapeutics, Inc Humanized and chimeric anti-factor c3 antibodies and uses thereof
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
PT2914291T (pt) 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações
KR20150088853A (ko) 2012-11-29 2015-08-03 바이엘 헬스케어 엘엘씨 활성화 단백질 c에 대한 인간화 모노클로날 항체 및 그의 용도
JP6505079B2 (ja) 2013-03-29 2019-04-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
KR102448976B1 (ko) 2013-08-07 2022-09-29 알렉시온 파마슈티칼스, 인코포레이티드 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질
WO2015054298A1 (en) * 2013-10-07 2015-04-16 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
JP6643244B2 (ja) 2014-02-27 2020-02-12 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 補体因子Ｂｂ抗体
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
CN116554320A (zh) 2016-10-12 2023-08-08 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DAMAGE
EP4257602A3 (en) * 2018-06-11 2023-12-27 Aarhus Universitet Single domain antibodies for complement regulation
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CN117295766A (zh) * 2021-03-19 2023-12-26 艾佩斯瑞生物制药公司 对唾液酸结合性ig样凝集素15具特异性的抗体及其用途
WO2024108529A1 (en) * 2022-11-25 2024-05-30 Linno Pharmaceuticals Inc. Properdin binding protein and use thereof
AU2022420788A1 (en) 2021-12-22 2024-05-16 Boehringer Ingelheim International Gmbh Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
KR20230105972A (ko) * 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
CN114874329A (zh) * 2022-05-19 2022-08-09 江苏大学 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用
EP4590697A2 (en) * 2022-09-20 2025-07-30 Visterra, Inc. Treatment of complement mediated diseases and disorders with c3b-antibodies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63503089A (ja) * 1986-04-11 1988-11-10 ニルソン，ウルフ，エル ヒトｃ３中のある抗原決定基に対する抗体調製物及びその使用並びにその生産
WO2006012621A2 (en) * 2004-07-23 2006-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating the alternative pathway of complement
WO2008118711A2 (en) * 2007-03-23 2008-10-02 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with human anti-factor c3 antibodies and use thereof
WO2008154251A2 (en) * 2007-06-07 2008-12-18 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
WO2009056631A2 (en) * 2007-11-02 2009-05-07 Novartis Ag Molecules and methods for modulating complement component

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2316446T3 (es) * 2000-04-29 2009-04-16 University Of Iowa Research Foundation Diagnostico y terapeutica para trastornos relacionados con la degeneracion macular.
US7838165B2 (en) * 2004-07-02 2010-11-23 Kabushiki Kaisha Toshiba Carbon fiber synthesizing catalyst and method of making thereof
MX2007006593A (es) * 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
KR20150139636A (ko) * 2005-10-12 2015-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
GB0613209D0 (en) * 2006-07-03 2006-08-09 Ucb Sa Methods

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63503089A (ja) * 1986-04-11 1988-11-10 ニルソン，ウルフ，エル ヒトｃ３中のある抗原決定基に対する抗体調製物及びその使用並びにその生産
WO2006012621A2 (en) * 2004-07-23 2006-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating the alternative pathway of complement
WO2008118711A2 (en) * 2007-03-23 2008-10-02 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with human anti-factor c3 antibodies and use thereof
WO2008154251A2 (en) * 2007-06-07 2008-12-18 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
WO2009056631A2 (en) * 2007-11-02 2009-05-07 Novartis Ag Molecules and methods for modulating complement component

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6014039079; ＴＯＳＩＣ，　Ｌ．，　ｅｔ　ａｌ．: Ｊｏｕｒｎａｌ　ｏｆ　Ｉｍｍｕｎｏｌｏｇｉｃａｌ　Ｍｅｔｈｏｄｓ １２０, 1989, ｐｐ．２４１-２４９ *
JPN6014039080; ＷＡＲＬ，　Ｋ．Ｌ．，　ｅｔ　ａｌ．: Ａｄｖａｎｃｅｄ　Ｄｒｕｇ　Ｄｅｌｉｖｅｒｙ　Ｒｅｖｉｅｗｓ ５８, 2006, ｐｐ．６５７-６７０ *
JPN6014039081; ＫＡＴＳＣＨＫＥ，　Ｋ．Ｊ．，　Ｊｒ．，　ｅｔ　ａｌ．: Ｊ．　Ｂｉｏｌ．　Ｃｈｅｍ． ２８４, 2009, ｐｐ．１０４７３-１０４７９ *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502023A (ja) * 2013-12-24 2017-01-19 ノーベルメッド セラピューティクス インコーポレイテッド． 眼疾患を治療する組成物および方法
US10183989B2 (en) 2013-12-24 2019-01-22 Novelmed Therapeutics, Inc. Methods of treating ocular diseases
US10696740B2 (en) 2013-12-24 2020-06-30 Novelmed Therapeutics, Inc. Methods of treating ocular diseases
JP2021520195A (ja) * 2018-04-03 2021-08-19 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Ｃ３結合薬及びその使用方法
US11767359B2 (en) 2018-04-03 2023-09-26 Ngm Biopharmaceuticals, Inc. C3-binding agents and methods of use thereof
JP7477457B2 (ja) 2018-04-03 2024-05-01 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Ｃ３結合薬及びその使用方法

Also Published As

Publication number Publication date
ECSP11011445A (es) 2012-01-31
CL2011002756A1 (es) 2012-03-23
EA201101593A1 (ru) 2012-06-29
IL216061A0 (en) 2012-01-31
CO6440515A2 (es) 2012-05-15
EP2427491A2 (en) 2012-03-14
TW201043638A (en) 2010-12-16
CA2760757A1 (en) 2010-12-02
PE20120899A1 (es) 2012-08-03
US20100291106A1 (en) 2010-11-18
SG175432A1 (en) 2011-12-29
UY32612A (es) 2010-12-31
AR076655A1 (es) 2011-06-29
MX2011011754A (es) 2011-11-29
MA33402B1 (fr) 2012-07-03
ZA201107551B (en) 2012-07-25
WO2010136311A2 (en) 2010-12-02
WO2010136311A3 (en) 2011-05-26
AU2010252156A1 (en) 2011-11-10
TN2011000528A1 (en) 2013-05-24
CN102459334A (zh) 2012-05-16
KR20120088551A (ko) 2012-08-08

Similar Documents

Publication Publication Date Title
JP6224657B2 (ja) 補体タンパク質ｃ５を標的とする抗体に関する組成物および方法
JP2012525829A (ja) 補体タンパク質Ｃ３ｂを標的とする抗体の組成物および方法
CN104114576B (zh) 用于抗体靶定p因子的组合物和方法
KR20160021823A (ko) 렉틴-유사 산화된 ldl 수용체1 항체 및 사용 방법
AU2014201433B2 (en) Compositions and methods for antibodies targeting complement protein C5
HK1202269B (en) Compositions and methods for antibodies targeting complement protein c5
HK1156226B (en) Compositions and methods for antibodies against complement protein c5
HK1157663B (en) Compositions and methods for antibodies targeting complement protein c5

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130501

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140916

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150310